References
- McConathy J, Owens MJ. Stereochemistry in Drug Action. Prim Care
Companion J Clin Psychiatry. 2003;5(2):70-73.
https://doi.org/10.4088/pcc.v05n0202.
- Abram M, Jakubiec M, Kaminski K. Chirality as an important factor for
the development of new antiepileptic drugs. Chem Med Chem.
2019;20(14):1744-1761. https://doi.org/ 10.1002/cmdc.201900367.
- Smith SW. Chiral toxicology: it’s the same thing…only different.
Toxicol Sci. 2009;110(1):4-30. https://doi.org/10.1093/toxsci/kfp097.
- Wei X, Liu J, Xia GJ, Deng J, Sun P, Chruma JJ, Wu W, Yang C, Wang YG,
Huang Z. Enantioselective photoinduced cyclodimerization of a
prochiral anthracene derivative adsorbed on helical metal
nanostructures. Nat Chem. 2020;12(6):551-559.
https://doi.org/10.1038/s41557-020-0453-0.
- Chmielewska A, Konieczna L, Bączek T. A novel two-step liquid-liquid
extraction procedure combined with stationary phase immobilized human
serum albumin for the chiral separation of cetirizine enantiomers
along with M and P parabens. Molecules. 2016;21(12):1654.
https://doi.org/10.3390/molecules21121654.
- Tillement JP, Testa B, Brée F. Compared pharmacological
characteristics in humans of racemic cetirizine and levocetirizine,
two histamine H1-receptor antagonists. Biochem Pharmacol.
2003;66(7):1123-6. https://doi.org/10.1016/s0006-2952(03)00558-6.
- Blaschke G, Kraft HP, Fickentscher K, Köhler F. Chromatographic
separation of racemic thalidomide and teratogenic activity of its
enantiomers. Arzneim.-Forsch. 1979;29(10):1640-1642.
- Tokunaga E, Yamamoto T, Ito E, Shibata N. Understanding the
thalidomide chirality in biological processes by the
self-disproportionation of enantiomers. Sci Rep. 2018;8(1):17131.
https://doi.org/10.1038/s41598-018-35457-6.
- Agranat I, Caner H. Intellectual property and chirality of drugs. Drug
Discovery Today. 1999;4(7):313-321.
https://doi.org/10.1016/s1359-6446(99)01363-x.
- Gal J. New single-isomer compounds on the horizon. CNS Spectr.
2002;7(4 Suppl 1):45-54. https://doi.org/10.1017/S1092852900028601.
- Tucker GT. Chiral switches. Lancet. 2000;355(9209):1085-7.
https://doi.org/10.1016/S0140-6736(00)02047-X.
- Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462
medicinal products because of adverse drug reactions: a systematic
review of the world literature. BMC Med. 2016;14:10.
https://doi.org/10.1186/s12916-016-0553-2.
- NIH National Center for Advancing Translational Sciences. Inxight:
Drugs. https://drugs.ncats.ioAccessed 13 Jan 2022.
- Nguyen LA, He H, Pham-Huy C. Chiral drugs: an overview. Int J Biomed
Sci. 2006;2(2):85-100.
- Katzung BG. Introduction: The Nature of Drugs & Drug Development &
Regulation. In: Katzung BG, eds. Basic & Clinical Pharmacology. 15th
ed. McGraw-Hill Education: US; 2020.p: 1-20.
- Caner H, Groner E, Levy L, Agranat I. Trends in the development of
chiral drugs. Drug Discov Today. 2004;9(3):105-10.
https://doi.org/10.1016/s1359-6446(03)02904-0.
- Lennard MS. Clinical pharmacology through the looking glass:
reflections on the racemate vs enantiomer debate. Br J Clin Pharmacol.
1991;31(6):623-625.
https://doi.org/10.1111/j.1365-2125.1991.tb05583.x.
- Mwamwitwa KW, Kaibere RM, Fimbo AM, Sabitii W, Ntinginya NE, Mmbaga
BT, Shewiyo DH, Shearer MC, Smith AD, Kaale EA. A Retrospective
Cross-sectional Study to Determine Chirality Status of Registered
Medicines in Tanzania. Sci Rep. 2020;10(17834).
https://doi.org/10.1038/s41598-020-74932-x.
- Lin GQ, Zhang JG, Cheng JF. Overview of Chirality and Chiral Drugs.
In: Chiral Drugs: Chemistry and Biological Action, 1st ed. Eds: Lin
GQ, Zhang JG, Cheng JF. John Wiley & Sons, Inc. 2011, p.
3–28. https://doi.org/10.1002/9781118075647.ch1.
- Agranat I, Caner H, Caldwell J. Putting chirality to work: the
strategy of chiral switches. Nat Rev Drug Discov. 2002;1(10):753-768.
https://doi.org/10.1038/nrd915.
- WHO Collaborating Centre for Drug Statistics Methodology, ATC
classification index with DDDs, 2021. Oslo, Norway 2020.
https://www.whocc.no/atc_ddd_index/ Accessed 29 Dec 2021.
- Fung M, Thornton A, Mybeck K, Wu JH, Hornbuckle K, Muniz E. Evaluation
of the Characteristics of Safety Withdrawal of Prescription Drugs from
Worldwide Pharmaceutical Markets-1960 to 1999. Drug Inf J.
2001;35(1):293-317. https://doi.org/10.1177/009286150103500134.
- Inotai A, Hankó B, Mészáros Á. Trends in the non-steroidal
anti-inflammatory drug market in six Central-Eastern European
countries based on retail information. Pharmacoepidemiol Drug Saf.
2010;19(2):183–90. https://doi.org/10.1002/pds.1893.
- Ranade VV, Somberg JC. Chiral cardiovascular drugs: an overview. Am J
Ther. 2005;12(5):439-59.
https://doi.org/10.1097/01.mjt.0000167429.37357.0c.
- Alomar MJ. Factors affecting the development of adverse drug reactions
(Review article). Saudi Pharm J. 2014;22(2):83-94.
https://doi.org/10.1016/j.jsps.2013.02.003.
- Gross AS, Somogyi A, Eichelbaum M. Stereoselective Drug Metabolism and
Drug Interactions. In: Eichelbaum M, Somogyi A eds, Stereochemical
Aspects of Drug Action and Disposition. Handbook of Experimental
Pharmacology, vol 153. Berlin: Springer; 2003, p:313-339.
https://doi.org/10.1007/978-3-642-55842-9_13.
- Faber K, Griengl H. Chirality in Organic Synthesis — The Use of
Biocatalysts. In: Janoschek R., eds. Chirality. Berlin: Springer;
1991, p:103-140.
- European Association for the Study of the Liver. EASL clinical
practice guidelines: Drug-induced liver injury. J Hepatol
2019;70:1222-61. https://doi.org/10.1016/j.jhep.2019.02.014.
- Walgren JL, Mitchell MD, Thompson DC. Role of metabolism in
drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol.
2005;35(4):325-61. https://doi.org/10.1080/10408440590935620.
- Jamal S, Ali W, Nagpal P, Grover S, Grover A. Computational models for
the prediction of adverse cardiovascular drug reactions. J Transl Med.
2019;17(1):171.
https://doi.org/10.1186/s12967-019-1918-z.
- Blaser HU. Chirality and its implications for the pharmaceutical
industry. Rend. Fis. Acc. Lincei 2013;24:213–216.
https://doi.org/10.1007/s12210-012-0220-2.